FibroBiologics shares are trading lower. The company announced that USPTO has issued patent for the therapeutic use of fibroblasts in wound healing.

FibroBiologics Says IP Australia Issues Notice Of Acceptance For Australian Patent Application Titled ‘Cellular Blend For The Regeneration Of Chondrocytes Or Cartilage Type Cells’

Accepted Patent Contains Claims Covering Methods of Combining Fibroblasts, Platelet Rich Plasma, and Nucleus Pulposus Conditioned Media to Regenerate Cartilage and Improve the Condition of Degenerated and Aged

8-K filing — FibroBiologics, Inc. (FBLG)

Filed: 2026-10-08 AccNo: 0001193125-26-418065 Size: 696 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits

FibroBiologics Files U.S. Patent Application For New Cell-Based Technology Designed To Continuously Produce Peptides Such As GLP-1, GIP and GLP-2 In The Body

Today, popular GLP-1 medicines used for weight loss and diabetes generally require patients to take regular weekly injections or daily pills. FibroBiologics is developing a different approach.The patent application

EXCLUSIVE: FibroBiologics Files US Patent Application For New Technology Designed To Produce GLP-1 And Other Therapeutic Peptides Inside The Body, As An Alternative To Repeated Injections